| Formulary Chapter 6: Endocrine system - Full Chapter
|
| 06.07 |
Other endocrine drugs |
|
|
| 06.07.01 |
Bromocriptine and other dopaminergic drugs |
|
|
| 06.07.02 |
Drugs affecting gonadotrophins |
|
|
| 06.07.02 |
Gonadorelin analogues |
|
|
| 06.07.02 |
Breast pain (mastalgia) |
|
|
Buserelin
 
|
Non Formulary
|
Black - Suprecur
Black - Suprefact
Black - Nasal Spray |
LEUPRORELIN ACETATE
(Staladex)
|
Non Formulary
|
|
TRIPTORELIN
(Gonapeptyl Depot)
|
Non Formulary
|
|
Key |
 |
Restricted Drug |
 |
Unlicensed |
|
|
Link to adult BNF
|
|
|
Link to children's BNF
|
|
|
Link to SPCs
|
|
Cytotoxic Drug |
|
Controlled Drug |
|
|
High Cost Medicine |
|
Cancer Drugs Fund |
|
NHS England |
|
Homecare |
|
ICB |
|
Low carbon footprint |
|
Medium carbon footprint |
|
High carbon footprint |
|
| Status |
Description |
|
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications |
|
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry. |
|
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry. |
|
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist. |
|
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only |
|
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information. |
|
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use. |
|
Check Notes as varies across the area |
|
|
